Experience
AbbVie Inc.
The Mathilda and Terence Kennedy Institute of Rheumatology Trust
The Southern District of New York (Judge Paul A. Crotty) ruled in favor of Finnegan client AbbVie, in a declaratory judgment action against its licensor The Mathilda and Terence Kennedy Institute of Rheumatology Trust (“Kennedy”). AbbVie brought this action because Kennedy claimed AbbVie would owe royalties on certain sales of its drug Humira®, despite AbbVie's assertion that the Kennedy patent at issue was invalid. Humira®is used by hundreds of thousands of patients to treat diseases such as rheumatoid arthritis and Crohn’s disease, and had revenues of more than $9 billion worldwide in 2012. After a four-day bench trial, the court held all of the claims of the Kennedy patent at issue were invalid for obviousness-type double-patenting. The court entered final judgment declaring all the claims at issue invalid, and declaring AbbVie the prevailing party and awarding costs. In a separate declaratory judgment case, the patents were invalidated by summary judgment both were affirmed on appeal.
AbbVie Inc. v. The Mathilda and Terence Kennedy Institute of Rheumatology Trust, 1:11-cv-02541; 1:13-cv-01358, S.D.N.Y., Judge Crotty
AbbVie Inc. v. The Mathilda and Terence Kennedy Institute of Rheumatology Trust, 13-1545; 14-1672, Fed. Cir., Judges Chen, Dyk, Wallach, Taranto
District court enters judgment of noninfringement for Finnegan client Philips
Koninklijke Philips Electronics N.V.
Eli Lilly and Company
Finnegan secures dismissal for lack of personal jurisdiction for client SK Innovation
SK Innovation Co. Ltd.
Hyundai Motor Co.; Kia Motors Corp.
ITC issues final determination in favor of Finnegan client SKC
SKC Kolon PI, Inc.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.